The pluripotency regulator Prdm14 initiates cancer by epigenetic mechanisms
多能性调节因子 Prdm14 通过表观遗传机制引发癌症
基本信息
- 批准号:8898738
- 负责人:
- 金额:$ 32.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-28 至 2018-05-31
- 项目状态:已结题
- 来源:
- 关键词:Acute T Cell LeukemiaAddressAdultAftercareAneuploidyAnimalsBehaviorBindingBiochemicalBiological AssayBreastCancer RelapseCell SeparationCellsChromatinChromosomal RearrangementColonComplexCopy Number PolymorphismCultured CellsDNADNA DamageDNA RepairDNA Repair PathwayDerivation procedureDevelopmentDiseaseDouble Strand Break RepairDrug resistanceEpigenetic ProcessEventFlow CytometryGene Expression ProfileGene TargetingGenesGeneticGenetic RecombinationGenomic InstabilityGenomic SegmentGenomic approachGoalsHealthHumanLifeLinkLymphoblastic LeukemiaMaintenanceMalignant NeoplasmsMediatingMessenger RNAMicroRNAsMiningModelingMolecularMolecular ProfilingMonitorMusMutationNOTCH1 geneOvarianPharmaceutical PreparationsPlayPropertyProteinsRNA SequencesRadiationRecurrent diseaseRelapseReporterRoleSET DomainSignal TransductionSomatic CellStem cellsStructure of primordial sex cellTherapeutic InterventionTissuesUntranslated RNAWorkX ChromosomeXenograft Modelanticancer researchbasecancer cellcancer initiationcancer preventioncancer typecell typechemotherapeutic agentchromatin remodelingclinically relevantcombinatorialdemethylationdesigngenome integrityhistone methyltransferasehuman datainterestleukemialung melanomamolecular markermouse modelpluripotencypreclinical studypreventprogramsprotein complexresearch studyresponseself-renewalstemtherapy resistanttranscription factortranscriptome sequencingtreatment strategytumortumor growthtumor progressiontumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Drug resistance and cancer relapse are attributed to the persistence of stem cells. The PR/SET domain protein PRDM14 regulates a cell's pluripotent potential to initiate and progress cancer through epigenetic events that are molecular signatures of stem cells. Normally, PRDM14 uses epigenetic mechanisms to establish the pluripotency of primordial germ cells, and its role in cancer is similar. PRDM14's widespread expression in many tumor types, including breast, ovarian, colon, lung, melanoma and lymphoblastic leukemia implies that it is commonly involved in epigenetic events to initiate cancer. This proposal challenges paradigms by suggesting that PRDM14 regulates a somatic cell's pluripotent potential to generate C-ICs as it promotes genomic instability, allowing it to cause tumors in many cell types. PRDM14 is a prime target for therapeutic intervention, because of its restricted expression to only a few cells in the body. Key to this project is that unique inducible mouse models will be exploited to examine events during tumor development, progression and relapse. Experiments that address three basic questions will be performed: what biochemical mechanisms does Prdm14 use to establish self-renewal to initiate cancer, how do the initiating cells maintain self-renewal in the tumor, and how does PRDM14 perturb genome integrity within these cells to progress malignancy? The first aim will use cutting edge genomic approaches to confirm Prdm14's binding targets and identify its protein partners, while it determines how Prdm14 alters chromatin to reset pluripotency in pre- leukemia cells. The second aim will determine the properties of Prdm14 pre-leukemia cells using flow cytometry, cellular and molecular profiling approaches. The third aim will determine how PRDM14 catalyzes chromosomal rearrangements, leading to copy number variation in the tumors that cause specific driver mutations such as activated NOTCH1 through recombination. These studies propose a genetic strategy to inhibit recombination and a drug treatment strategy designed against targets downstream of PRDM14's action to prevent the growth of tumors in the mouse model. The mouse models allow the behavior of cancer cells to be monitored from the beginning, mark cells for isolation, and follow their lineage potential. Data from human tumors will be mined and compared with mouse tumors throughout the study and mouse leukemia will be compared with human leukemia in Aim 3 to demonstrate clinical relevance. Although mouse leukemia models are exploited, the work will have far-reaching applications to all cancers. PRDM14's limited normal expression in adults indicates that PRDM14 or its initial regulatory targets are key candidates for a therapy directed against cells that express it abnormally. Therefore, PRDM14 could prove to be a universal target in C-ICs.
描述(由申请人提供):耐药性和癌症复发归因于干细胞的持久性。PR/SET结构域蛋白PRDM 14通过作为干细胞分子特征的表观遗传事件调节细胞的多能潜能以引发和发展癌症。通常,PRDM 14使用表观遗传机制来建立原始生殖细胞的多能性,其在癌症中的作用类似。PRDM 14在包括乳腺癌、卵巢癌、结肠癌、肺癌、黑色素瘤和淋巴母细胞白血病在内的许多肿瘤类型中的广泛表达意味着它通常参与表观遗传事件以引发癌症。该提案通过表明PRDM 14调节体细胞的多能潜能以产生C-IC来挑战范式,因为它促进基因组不稳定性,使其能够在许多细胞类型中引起肿瘤。PRDM 14是治疗干预的主要靶标,因为其仅在体内少数细胞中限制表达。该项目的关键是将利用独特的诱导型小鼠模型来检查肿瘤发生、进展和复发期间的事件。将进行解决三个基本问题的实验:Prdm 14使用什么生化机制来建立自我更新以引发癌症,启动细胞如何在肿瘤中保持自我更新,以及PRDM 14如何扰乱这些细胞内的基因组完整性以发展恶性肿瘤?第一个目标将使用尖端的基因组方法来确认Prdm 14的结合靶点并识别其蛋白质伴侣,同时确定Prdm 14如何改变染色质以重置白血病前细胞的多能性。第二个目标将使用流式细胞术、细胞和分子分析方法确定Prdm 14前白血病细胞的特性。第三个目标将确定PRDM 14如何催化染色体重排,导致肿瘤中的拷贝数变异,从而导致特定的驱动突变,例如通过重组激活NOTCH 1。这些研究提出了一种抑制重组的遗传策略和一种针对PRDM 14作用下游靶点设计的药物治疗策略,以防止小鼠模型中肿瘤的生长。小鼠模型允许从一开始就监测癌细胞的行为,标记细胞进行分离,并跟踪其谱系潜力。在整个研究期间,将采集人肿瘤数据并与小鼠肿瘤进行比较,在目标3中,将小鼠白血病与人白血病进行比较,以证明临床相关性。虽然小鼠白血病模型被利用,但这项工作将对所有癌症产生深远的应用。PRDM 14在成人中有限的正常表达表明,PRDM 14或其初始调节靶标是针对异常表达它的细胞的治疗的关键候选物。因此,PRDM 14可以被证明是C-IC中的通用目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MONICA J. JUSTICE其他文献
MONICA J. JUSTICE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MONICA J. JUSTICE', 18)}}的其他基金
The pluripotency regulator Prdm14 initiates cancer by epigenetic mechanisms
多能性调节因子 Prdm14 通过表观遗传机制引发癌症
- 批准号:
9267938 - 财政年份:2014
- 资助金额:
$ 32.98万 - 项目类别:
The pluripotency regulator Prdm14 initiates cancer by epigenetic mechanisms
多能性调节因子 Prdm14 通过表观遗传机制引发癌症
- 批准号:
8844112 - 财政年份:2014
- 资助金额:
$ 32.98万 - 项目类别:
The pluripotency regulator Prdm14 initiates cancer by epigenetic mechanisms
多能性调节因子 Prdm14 通过表观遗传机制引发癌症
- 批准号:
8583023 - 财政年份:2013
- 资助金额:
$ 32.98万 - 项目类别:
Consortium for Broad Based Disease Phenotyping of Knockout Mice
基因敲除小鼠广泛疾病表型联盟
- 批准号:
8626464 - 财政年份:2011
- 资助金额:
$ 32.98万 - 项目类别:
Consortium for Broad Based Disease Phenotyping of Knockout Mice
基因敲除小鼠广泛疾病表型联盟
- 批准号:
8189488 - 财政年份:2011
- 资助金额:
$ 32.98万 - 项目类别:
Consortium for Broad Based Disease Phenotyping of Knockout Mice
基因敲除小鼠广泛疾病表型联盟
- 批准号:
8333401 - 财政年份:2011
- 资助金额:
$ 32.98万 - 项目类别:
Consortium for large-scale production and cryopreservation of knockout mice
基因敲除小鼠大规模生产和冷冻保存联盟
- 批准号:
8189478 - 财政年份:2011
- 资助金额:
$ 32.98万 - 项目类别:
CONSORTIUM FOR LARGE-SCALE PRODUCTION AND CRYOPRESERVATION KNOCKOUT MICE: AIDS
大规模生产和低温保存敲除小鼠联盟:艾滋病
- 批准号:
8356913 - 财政年份:2011
- 资助金额:
$ 32.98万 - 项目类别:
Consortium for large-scale production and cryopreservation of knockout mice
基因敲除小鼠大规模生产和冷冻保存联盟
- 批准号:
8325929 - 财政年份:2011
- 资助金额:
$ 32.98万 - 项目类别:
CONSORTIUM FOR LARGE-SCALE PRODUCTION AND CRYOPRESERVATION OF KNOCKOUT MICE
基因敲除小鼠大规模生产和冷冻保存联盟
- 批准号:
8356914 - 财政年份:2011
- 资助金额:
$ 32.98万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 32.98万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 32.98万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 32.98万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 32.98万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 32.98万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 32.98万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 32.98万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 32.98万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 32.98万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 32.98万 - 项目类别:
Research Grant